期刊文献+

原发型心肌淀粉样变性的诊断及治疗研究进展 被引量:1

下载PDF
导出
摘要 原发型心肌淀粉样变性(CA)是错误折叠的免疫球蛋白轻链在心肌的细胞外空间沉积,导致心脏功能障碍的恶性浆细胞疾病〔1~4〕。在美国,原发型CA每年的发病率约为1/100 000或2 500~5 000例新发病例〔5〕。我国尚无明确的流行病学统计。原发型CA早期以心脏舒张功能障碍为主,随着疾病的进展,最终表现为心脏的收缩功能障碍。心功能不全的严重程度是发病率和死亡率的主要决定因素〔6〕。原发型CA发病较晚,患者多为中老年人,平均年龄为65岁,男性多见。该病预后差,进展迅速,未经治疗原发型CA患者的中位生存期不超过6个月〔5〕。本文就原发型CA的发病机制、临床诊断及治疗方面进行综述。
出处 《中国老年学杂志》 CAS 北大核心 2019年第15期3825-3829,共5页 Chinese Journal of Gerontology
基金 国家自然科学基金面上项目资助课题(81670343) 吉林省科技发展计划项目(20190701066GH)
  • 相关文献

参考文献1

二级参考文献36

  • 1Katzmann JA,Kyle RA,Benson J,et al.Screening panels for detection of monoclonal gammopathies.Clin Chem,2009;55(8):1517-1522.
  • 2Vrana JA,Theis JD,Dasari S,et al.Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics.Haematologica,2014.
  • 3Dispenzieri A,Gertz MA,Kyle RA,et al.Serum cardiac troponins and N-terminal pro-brain natriuretic peptide:A staging system for primary systemic amyloidosis.J Clin Oncol,2004;22(18):3751-3757.
  • 4Kumar S,Dispenzieri A,Lacy MQ,et al.Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements.J Clin Oncol,2012;30(9):989-995.
  • 5Palladini G,Dispenzieri A,Gertz MA,et al.New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers:Impact on Survival Outcomes.J Clin Oncol,2012;30(36):4541-4549.
  • 6Kyle RA,Gertz MA,Greipp PR,et al.A trial of three regimens for primary amyloidosis:Colchicine alone,melphalan and prednisone,and melphalan,prednisone,and colchicine.N Engl J Med,1997;336(17):1202-1207.
  • 7Palladini G,Russo P,Nuvolone M,et al.Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis.Blood,2007;110(2):787-788.
  • 8Jaccard A,Moreau P,Leblond V,et al.High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.N Engl J Med,2007;357(11):1083-1093.
  • 9Palladini G,Russo P,Lavatelli F,et al.Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan,dexamethasone,and thalidomide.Ann Hematol,2009;88(4):347-350.
  • 10Dietrich S,Schonland SO,Benner A,et al.Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement.Blood,2010;116(4):522-528.

共引文献10

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部